回复:Noel W. Clarke, Andrew J. Armstrong, Mototsugu Oya,等。奥拉帕尼加阿比特龙与安慰剂加阿比特龙一线治疗无症状/轻度症状和有症状转移性阉切抵抗性前列腺癌的疗效和安全性:来自3期PROpel试验的分析Eur Eur Eur Eur Eur。在出版社。https://doi.org/10.1016/j.euo.2024.09.013。
{"title":"回复:Noel W. Clarke, Andrew J. Armstrong, Mototsugu Oya,等。奥拉帕尼加阿比特龙与安慰剂加阿比特龙一线治疗无症状/轻度症状和有症状转移性阉切抵抗性前列腺癌的疗效和安全性:来自3期PROpel试验的分析Eur Eur Eur Eur Eur。在出版社。https://doi.org/10.1016/j.euo.2024.09.013。","authors":"Shiwang Yuan, Peng Chen, Fa Sun, Tao Li","doi":"10.1016/j.euf.2024.11.014","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":12160,"journal":{"name":"European urology focus","volume":" ","pages":""},"PeriodicalIF":4.8000,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Re: Noel W. Clarke, Andrew J. Armstrong, Mototsugu Oya, et al. Efficacy and Safety of Olaparib Plus Abiraterone Versus Placebo Plus Abiraterone in the First-line Treatment of Patients with Asymptomatic/Mildly Symptomatic and Symptomatic Metastatic Castration-resistant Prostate Cancer: Analyses from the Phase 3 PROpel Trial. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2024.09.013.\",\"authors\":\"Shiwang Yuan, Peng Chen, Fa Sun, Tao Li\",\"doi\":\"10.1016/j.euf.2024.11.014\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":12160,\"journal\":{\"name\":\"European urology focus\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":4.8000,\"publicationDate\":\"2025-02-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European urology focus\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.euf.2024.11.014\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European urology focus","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.euf.2024.11.014","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
Re: Noel W. Clarke, Andrew J. Armstrong, Mototsugu Oya, et al. Efficacy and Safety of Olaparib Plus Abiraterone Versus Placebo Plus Abiraterone in the First-line Treatment of Patients with Asymptomatic/Mildly Symptomatic and Symptomatic Metastatic Castration-resistant Prostate Cancer: Analyses from the Phase 3 PROpel Trial. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2024.09.013.
期刊介绍:
European Urology Focus is a new sister journal to European Urology and an official publication of the European Association of Urology (EAU).
EU Focus will publish original articles, opinion piece editorials and topical reviews on a wide range of urological issues such as oncology, functional urology, reconstructive urology, laparoscopy, robotic surgery, endourology, female urology, andrology, paediatric urology and sexual medicine. The editorial team welcome basic and translational research articles in the field of urological diseases. Authors may be solicited by the Editor directly. All submitted manuscripts will be peer-reviewed by a panel of experts before being considered for publication.